Weiwei Shen,Hailin Pang,Bo Xin et al. Weiwei Shen et al.

Subsequently to the publication of the above article, the authors contacted the Editorial Office to explain that, for the cell migration and invasion assay experiments shown in Fig. 3 on p. 1358, the same data had inadvertently been selecte...

Yiqian Liu,Ling Zhang,Jian Wang et al. Yiqian Liu et al.

Abnormally expressed long non-coding (lnc)RNAs are closely associated with the pathogenesis of non-small cell lung cancer (NSCLC); thus, the present study aimed to investigate the potential role of SNHG12 in NSCLC. Transmission electron mic...

Hideto Iguchi,Takahiro Kaki,Yuhei Harutani et al. Hideto Iguchi et al.

Introduction: Neoadjuvant chemoimmunotherapy is increasingly regarded as the standard treatment for resectable non-small cell lung cancer. Although it improves survival outcomes, immune-related adverse events can delay or...

Ziwei Wang,Kunpeng Xu,Han Sun et al. Ziwei Wang et al.

Purpose: This study evaluates the impact of thoracic radiotherapy (TRT) combined with immune checkpoint inhibitors (ICIs) treatment-related pneumonitis on tumor progression and prognosis in patients with non-small cell lu...

Vera Damuzzo,Lorenzo Gasperoni,Luna Del Bono et al. Vera Damuzzo et al.

Introduction: Anaplastic lymphoma kinase (ALK) inhibitors (ALKi) are the standard treatment for metastatic, ALK-positive non-small cell lung cancer (NSCLC). Second- and third-generation ALKi, including alectinib, brigatin...

Shuang Yan,Hua Jiang,Li Gong et al. Shuang Yan et al.

The diagnostic accuracy of ROSE in classifying lung cancer subtypes-specifically small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), squamous cell carcinoma (SCC), and adenocarcinoma (AC)-was systematically evaluated.

Yanqing Pan,Lingxin Yan,Shaoxi Wang et al. Yanqing Pan et al.

SMARC4 is the catalytic subunit of the SWI/SNF chromatin remodeling complex and is one of the most common altered chromatin remodeling ATPases in cancer. Studies have indicated that SMARCA4 loss is associated with highly aggressive tumors, ...

Blerina Resuli,Heidi Galarza,Diego Kauffmann-Guerrero et al. Blerina Resuli et al.

Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has demonstrated significant clinical activity and tolerability in EGFR-positive non-small cell lung cancer (NSCLC) patients. However, ac...

Shiwei Xu,Xin Sun,Yexin Gu et al. Shiwei Xu et al.

The heterogeneity and complex extracellular matrix (ECM) characteristics of non-small cell lung cancer (NSCLC) present significant challenges for understanding its pathological mechanisms and advancing precise treatment strategies. This stu...

Shichao Zhou,Wanchen Zhai,Qian Zhang et al. Shichao Zhou et al.

Background: Chemoimmunotherapy has emerged as the standard first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), improving survival outcomes.